Connect with us

Micro Cap Insider

Hiru Corporation (HIRU) Major Move Brewing as Water & Ice Shop Ups Daily Production Capacity to 100 Tons of Tubed Ice (CE Removed now Pink Current)

Published

on

Hiru Corporation (HIRU) continues to move steadily higher with power in recent days after a brief dip below the $0.01 mark. HIRU is emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation HIRU is moving steadily northbound with many new investors buying in every day. HIRU is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – HIRU is looking to take out $0.035 recent highs for confirmation of the next leg up and blue sky breakout!  

Its easy got get excited about HIRU since new CEO Kathryn Gavin took over the Company with extensive experience in commercial water and ice manufacturing, production, and sale as described under S.I.C. Code 4981 (Water Supply) and S.I.C. Code 2097 (Manufactured Ice). Since her arrival in Arizona, Ms. Gavin has researched, located, and is in current negotiations to acquire several high-profile cash flow positive business operations in the State of Arizona in these two particular S.I.C. code industries which she plans to bring to the public markets through the HIRU Corporation. HIRU already operates its flagship property is the Water & Ice Shop offering consumers across Arizona with bagged ice and bottled water. In Phoenix, Arizona the Company has cutting-edge production and distribution facilities with a daily production capacity of about 100 tons of tubed ice and a well-maintained fleet of over 10 refrigerated trucks and trailers.  HIRU has just has

he ce removed and is now listed as “”pink current”on otcmarkets.

Water and IceHiru Corporation (HIRU) operating out of Phoenix, Arizona is a water and ice company looking for new business in the Arizona area. The Company’s flagship property is Water & Ice Shop offering consumers across Arizona with bagged ice and bottled water. In Phoenix, Arizona the Company has cutting-edge production and distribution facilities. Water & Ice Shop tries to set the bar high and provide great customer service to its diverse client base as well as its retail partners. 

The Company is completely equipped to manage all of its customers’ demands, with a daily production capacity of about 100 tons of tubed ice and a well-maintained fleet of over 10 refrigerated trucks and trailers. The Company provides weekly route service to its reselling partners and works carefully to manage all of your unique events and occasions, seven days a week. Water & Ice Shop is happy to rent its Freezer Boxes and Trailers for all of your special events, and we offer white glove service for all of your Bagged Ice and Bottled Water needs. All of Water & Ice Shop retail clients receive dedicated weekly servicing at a minimum, ensuring that they are never out of merchandise. Water & Ice Shop ensures that several deliveries are made as needed, taking into account seasonality and client demands. A well-trained crew of drivers and assistance manage a huge fleet of refrigerated trucks and trailers. 

https://twitter.com/lgw1000/status/1408385085011812352

To Find out the inside Scoop on HIRU Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HIRU

In March Kathryn Gavin was named as the new sole officer and director of the Company. Ms. Kathryn Gavin has had numerous professional management positions during her career including being the former sole officer and director of UMAX Group Corp., a Nevada corporation, a pink sheet company trading under the ticker symbol “UMAX (e.g. from June 1, 2018 to December 31, 2018). During her short time with UMAX, Ms. Gavin assisted in rectifying many corporate governance issues and attempted to finalize several strategic acquisitions before moving her business interest to a more lucrative business opportunity she identified in commercial water and ice manufacturing, production, and sale as described under S.I.C. Code 4981 (Water Supply) and S.I.C. Code 2097 (Manufactured Ice). 

This new industry focus was the impetus to her moving to Scottsdale, Arizona in the Summer of 2020.(SHE MOVED HERE SOLELY TO FOCUS ON HIRU….) Since her arrival in Arizona, Ms. Gavin has researched, located, and is in current negotiations to acquire several high-profile cash flow positive business operations in the State of Arizona in these two particular S.I.C. code industries which she plans to bring to the public markets through the HIRU Corporation. 

There is a lot of speculation which Companies the new CEO will merge into HIRU besides the preveiously announced Water & Ice Shop with a daily production capacity of about 100 tons of tubed ice and a well-maintained fleet of over 10 refrigerated trucks and trailers.  There is much speculation that Arizona custom bottled Water will also be included as it shares the same address as Water & Ice Shop. AZ Custom Bottled Water was founded in 2007. Continuous growth over the years necessitated expansion and in 2017 the company was acquired by the current ownership group. Today, AZ Custom Bottled Water operates out of an 11,000 sq. foot state-of-the-art bottling and distribution facility located in Phoenix, AZ. We are still a locally owned family business that believes in putting the customer first. Our mission is to deliver the best purified drinking water possible on time, every time. 

For more on HIRU Subscribe Right Now!

HIRU continues to move steadily higher with power in recent days after a brief dip below the $0.01 mark. HIRU is emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation HIRU is moving steadily northbound with many new investors buying in every day. HIRU is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – HIRU is looking to take out $0.035 recent highs for confirmation of the next leg up and blue sky breakout!  Its easy got get excited about HIRU since new CEO Kathryn Gavin took over the Company with extensive experience in commercial water and ice manufacturing, production, and sale as described under S.I.C. Code 4981 (Water Supply) and S.I.C. Code 2097 (Manufactured Ice). Since her arrival in Arizona, Ms. Gavin has researched, located, and is in current negotiations to acquire several high-profile cash flow positive business operations in the State of Arizona in these two particular S.I.C. code industries which she plans to bring to the public markets through the HIRU Corporation. HIRU already operates its flagship property is the Water & Ice Shop offering consumers across Arizona with bagged ice and bottled water. In Phoenix, Arizona the Company has cutting-edge production and distribution facilities with a daily production capacity of about 100 tons of tubed ice and a well-maintained fleet of over 10 refrigerated trucks and trailers. We will be updating on HIRU when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HIRU.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HIRU either long or short and we have not been compensated for this article.

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Featured

Femasys’ (NASDAQ: FEMY) FemaSeed Receives FDA Nod: A Game-Changer for Infertility Treatment

Published

on

Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.

FemaSeed:

It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.

Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.

Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.

But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.

In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.

We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by DigitalMarketingAgency from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.